Image source: Getty Images.
Continue Reading Below
Shares ofIntra-Cellular Therapies(NASDAQ: ITCI), a clinical-stage biopharma focused on diseases of the central nervous system, are falling by more than 62% as of 10:45 a.m. EDT on Thursday.
The decline can be traced to the company reporting results from a phase 3 trial testing its lead compound ITI-007 as a potential treatment for schizophrenia.
Patients in the study were randomized into four groups and were either given a 60 mg dose of ITI-007, a 20 mg dose of ITI-007, a placebo, or risperidone, the latter of which is a commonly prescribed antipsychotic. The primary outcome of the six-week study was to report the change from baseline on thePositive and Negative Syndrome Scale, or PANSS, a test that measures the antipsychotic behavior of patients with schizophrenia.
Both the 60 mg and 20 mg versions of ITI-007 showed achange from baseline on the PANSS total score of -14.6 points and -15.0 points, respectively, which was consistent with prior studies. However, both of those numbers fell short of the -15.1 point change that was observed in the placebo group. In addition, patients who used risperidone did even better, posting a total score of -20.5 points.
These results suggestthat ITI-007 may not be an effective treatment for schizophrenia,hence why shares of Intra-Cellular are cratering today.
Management is blaming the poor study results on "anunusually high placebo response." They have a point, since in a prior phase 3 schizophrenia study, the placebo group produced a PANSS score of -10.3 points. That's nearly five points lower than the results observed in this study.
However, that point overlooks the fact that patients who used risperidone showed a total PANSS score of -20.5, which was much better than either dose of ITI-007.
On the plus side, ITI-007 once again excelled from a safety perspective, showing clinical results that were consistent with the placebo group. That compares favorably to risperidone, as patients who used this drug showed astatisticallysignificantincrease in weight, glucose, cholesterol, triglycerides, and prolactin when compared to placebo.
In the press release, Dr. Sharon Mates, Intra-Cellular Therapies' CEO, stated: "We remain committed to thedevelopment of ITI-007 for the treatment of schizophrenia, bipolar depression, agitation associated with dementia, including Alzheimer's disease and other neuropsychiatric indications." The company also said that is will be meetingwith the Food and Drug Administration to discuss next steps. However, it is unknown at this point if the agency would accept a submission with the data that the company has on hand or if it would require an additional phase 3 study.
Intra-Cellular ended June with more than$442 million in cash, so it certainly has the funds to run another trial if necessary. However, I'd argue that this clinical data substantially raises the risk profile of an already high-risk stock. For that reason, I'd recommendthat potential investors should approach this company with caution.
A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Brian Feroldi has no position in any stocks mentioned.Like this article? Follow him onTwitter where he goes by the handle@Longtermmindsetor connect with him on LinkedIn to see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.